Screener
Rigel Pharmaceuticals RIGL Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenues: | ||
| Product sales, net | $54,923 | $43,550 |
| Contract revenues from collaborations | 3,895 | 9,783 |
| Total revenues | 58,818 | 53,333 |
| Costs and expenses: | ||
| Cost of product sales | 4,606 | 4,409 |
| Research and development | 11,676 | 8,436 |
| Selling, general and administrative | 30,651 | 27,715 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's total revenue?
- Rigel Pharmaceuticals (RIGL) reported total revenue of $58.82M in Q1 2026.
- How has Rigel Pharmaceuticals's total revenue changed year-over-year?
- Rigel Pharmaceuticals's total revenue increased by 10.3% year-over-year, from $53.33M to $58.82M.
- What is the long-term trend for Rigel Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's total revenue has grown at a 18.5% compound annual growth rate (CAGR), from $149.24M to $294.28M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Rigel Pharmaceuticals's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude